Moxifloxacin is an oral 8-methoxyquinolone antimicrobial that is used in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia[3]. The antibacterial spectrum of moxifloxacin includes all major upper and lower respiratory tract pathogens[4]. Concentrations of mocifloxacin equal to and greater than the MIC (range 0.125 to 1μg/ml) prevented the formation of filopodium-like projections, and changes in the morphological aspects of the intracellular bacteria. It is also appeared to have a protective effect against macrophage lysis, as many cells were still viable after 24h of incubation[5]. Moxifloxacin (12 mg/kg; intravenous injection; once-three times per day; for 7 days; white male Wistar rats) treatment every 8 hours is accompanied by longer survival. Tissue cultures 30 hours after bacterial challenge shows considerably less bacterial overgrowth in the spleens and lungs of moxifloxacin-treated than in salinetreated animals and without being toxic[6].
搜索
